When do the patents on INVERSINE expire, and when will INVERSINE go generic?

Sponsor	Phase
Yale University	Phase 3
National Alliance for Research on Schizophrenia and Depression	Phase 3
Autism Speaks	Phase 1

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Targacept	INVERSINE	mecamylamine hydrochloride	TABLET;ORAL	010251-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: October 23, 2026

INVERSINE is the legacy U.S. brand for mecamylamine hydrochloride, an oral ganglionic blocker approved for hypertension. Its commercial profile is that of a mature, niche prescription product rather than a growth pharmaceutical asset. Public filings do not report standalone INVERSINE revenue, unit sales, or product-level margins. The product’s value is constrained by limited clinical use, generic or equivalent mecamylamine availability, low prescriber demand, and the absence of meaningful modern exclusivity.

What is INVERSINE and who owns the product?

INVERSINE contains mecamylamine hydrochloride, a nicotinic acetylcholine receptor antagonist that reduces sympathetic and parasympathetic ganglionic transmission. The original approved use was treatment of moderate-to-severe hypertension, particularly where other antihypertensive therapies were inadequate or unsuitable (U.S. Food and Drug Administration [FDA], n.d.-a).

Product attribute	Data
Brand	INVERSINE
Active ingredient	Mecamylamine hydrochloride
Dosage form	Oral tablet
Historical strength	2.5 mg
Therapeutic class	Ganglionic blocker
Original indication	Hypertension
Regulatory pathway	Legacy 505(b)(1) NDA
Original approval period	1950s
Current commercial profile	Mature, niche, low-volume product
Biosimilar relevance	None; mecamylamine is a small molecule

Mecamylamine was introduced before the modern Hatch-Waxman framework. Its historical FDA approval predates the patent and exclusivity structures that now support branded pharmaceutical pricing. The brand therefore does not have the commercial protection associated with newer products that combine composition-of-matter patents, formulation patents, regulatory exclusivity, and active life-cycle management.

What is the FDA and Orange Book status of INVERSINE?

INVERSINE is associated with an old FDA-approved mecamylamine product record, but commercial availability and listing status have changed over time. FDA databases distinguish between an approved application, a product marketed under that application, and a product that has been discontinued from commercial distribution.

The relevant regulatory questions are:

Whether the NDA remains approved.
Whether the branded product is currently marketed.
Whether FDA lists a therapeutically equivalent product.
Whether the discontinuation was for commercial reasons rather than safety or efficacy concerns.

For legacy products such as INVERSINE, an FDA listing does not establish active supply. The Orange Book can retain a product or application record after a product has stopped being distributed. FDA’s discontinued-drug records are therefore more relevant to current market access than the historical approval alone (FDA, n.d.-b).

The product’s regulatory position does not create a meaningful barrier to competition. Mecamylamine is an established small-molecule active ingredient, and any current applicant would generally evaluate an abbreviated or other applicable approval route based on the status of the reference product and FDA’s product-specific requirements.

When did INVERSINE lose exclusivity?

INVERSINE lost practical market exclusivity decades ago. Its original approval occurred before the modern five-year new chemical entity exclusivity system and before current patent-term restoration rules. Any historical patents covering mecamylamine or its original formulation have expired.

Exclusivity category	INVERSINE position
New chemical entity exclusivity	Not available under the modern framework
Original composition patent	Expired
Formulation patents	No known active commercially material protection
Method-of-use patents	No known active blocking protection for the original hypertension indication
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
Current practical exclusivity	None established

The commercial consequence is important: a seller of mecamylamine cannot rely on patent-based pricing power comparable to a recently approved branded drug. Any premium would have to come from supply reliability, manufacturing quality, distributor relationships, clinical familiarity, or scarcity.

How many patents cover INVERSINE?

No active, commercially material patent estate is publicly associated with the historical INVERSINE hypertension product. The original active ingredient is long off patent. There is no established evidence of a current patent covering the basic mecamylamine molecule, the legacy 2.5 mg tablet, or the original hypertension method of use.

Potentially relevant later intellectual property has focused on different uses of mecamylamine, especially CNS applications and smoking cessation. Those patents would not automatically protect the INVERSINE hypertension product. Patent scope depends on the asserted claims, expiration dates, prosecution history, and the specific dosage regimen.

What formulations are protected by INVERSINE patents?

No active formulation patent is identified as a material commercial barrier for the legacy INVERSINE tablet. The product’s historical tablet formulation is technically straightforward compared with modified-release tablets, transdermal systems, long-acting injectables, or complex drug-device combinations.

A future formulation could seek protection for:

Modified-release mecamylamine.
Lower-dose tablets designed to reduce adverse effects.
Combination products for hypertension.
Transdermal or buccal delivery.
CNS-targeted dosing regimens.
Formulations designed for smoking cessation or neuropsychiatric use.

Those products would be separate life-cycle-management assets. They would not restore exclusivity to the original INVERSINE tablet unless supported by valid claims and commercial regulatory approval.

What is the financial trajectory of INVERSINE?

INVERSINE has no publicly disclosed standalone revenue trajectory. Public-company filings generally aggregate sales by product portfolio, therapeutic area, or business segment. No reliable public dataset establishes annual INVERSINE revenue, gross margin, prescription volume, or market share.

Its financial trajectory can be characterized as follows:

Period	Commercial condition	Financial implication
1950s-1970s	Established antihypertensive before modern multidrug therapy	Broad historical utility
1980s-1990s	Replaced by safer and more convenient antihypertensives	Demand contraction
2000s	Legacy and specialized use	Niche revenue potential
2010s	Research interest in mecamylamine’s CNS effects	Development value separated from brand value
Current market	Limited, low-volume opportunity	No visible blockbuster economics

The main causes of revenue decline are clinical substitution and product economics. Modern hypertension treatment relies on diuretics, ACE inhibitors, angiotensin receptor blockers, calcium-channel blockers, beta blockers, and fixed-dose combinations. These therapies generally have better tolerability, simpler titration, and stronger guideline support than ganglionic blockade.

Mecamylamine can cause orthostatic hypotension, constipation, urinary retention, blurred vision, dry mouth, and other anticholinergic or autonomic effects. Those tolerability issues reduce routine use and limit the addressable hypertension market.

What market dynamics affect INVERSINE?

Therapeutic substitution is the principal demand constraint

INVERSINE competes primarily against therapeutic alternatives rather than against another branded ganglionic blocker. Physicians can choose from multiple inexpensive generic antihypertensives with extensive clinical experience and guideline support.

This makes the product’s market highly defensive. Demand is more likely to come from:

Patients who cannot tolerate standard agents.
Historical prescribers familiar with mecamylamine.
Highly specialized hypertension cases.
Research and investigational use.
Patients requiring a specific pharmacologic mechanism.

Supply reliability can matter more than brand recognition

For old, low-volume drugs, market failure can arise from manufacturing economics rather than lack of clinical utility. Small production runs, active pharmaceutical ingredient sourcing, quality-control obligations, and distributor inventory requirements can reduce the incentive to maintain commercial supply.

A manufacturer with dependable production could capture a disproportionate share of the addressable market without holding patent exclusivity. The market would remain small, but scarcity could support premium pricing in some channels.

Research use creates optionality but not established revenue

Mecamylamine has been investigated in smoking cessation and neuropsychiatric applications because of its activity at nicotinic receptors. Targacept developed mecamylamine-related programs, including TC-5214, as a potential adjunctive treatment for major depressive disorder. AstraZeneca entered a development and commercialization relationship around TC-5214, but the program did not produce an approved replacement market for INVERSINE (Targacept, Inc., 2011; AstraZeneca, 2012).

Investigational development therefore added strategic interest to the molecule without creating a durable branded revenue stream. The failure or discontinuation of later-stage development materially limits the probability that INVERSINE will be transformed into a large commercial CNS product.

Which companies challenged or competed with INVERSINE?

There is no major current Paragraph IV campaign associated with INVERSINE comparable to challenges against high-revenue patented medicines. The competitive structure is fragmented:

Competitor group	Competitive effect
Generic antihypertensive manufacturers	Strong substitution pressure
Other mecamylamine suppliers	Potential direct price and supply competition
Compounded-product pharmacies	Limited, case-specific supply alternative
Research developers	Potential future-use competition rather than current brand competition
Manufacturers of modern antihypertensives	Dominant clinical alternatives

Because the molecule is old and the principal hypertension use is unprotected, a Paragraph IV litigation strategy would have limited commercial significance unless a newly listed patent covered a specific formulation or use.

What patent litigation and settlement agreements affect INVERSINE?

No material, current patent litigation or settlement agreement is publicly associated with the legacy INVERSINE hypertension product. There is no established Orange Book patent dispute that defines market entry timing.

Any future litigation would more likely concern:

A newly developed formulation.
A CNS method of use.
A combination product.
Trade secrets or manufacturing processes.
Regulatory exclusivity for a new indication.

The original tablet would remain exposed to competition because expired composition and use patents do not prevent commercial entry.

Does INVERSINE face biosimilar risk?

No. Biosimilar rules apply to biologic products, not to mecamylamine hydrochloride. INVERSINE faces generic-drug and alternative-therapy risk, not biosimilar risk.

The relevant regulatory pathway is an abbreviated small-molecule framework where applicable. Bioequivalence, chemistry and manufacturing controls, labeling, dosage-form similarity, and reference-product status would determine the practical entry requirements.

What generic launch scenarios exist for INVERSINE?

Scenario 1: Continued niche supply

A manufacturer maintains limited production for a small but stable patient population. Revenue remains modest, with value derived from reliable supply rather than exclusivity.

Scenario 2: Market withdrawal

Low demand or manufacturing costs make the product uneconomic. Patients and prescribers move to compounded supply, alternative therapy, or another source of mecamylamine.

Scenario 3: Premium shortage market

A limited number of suppliers maintain access while inventories remain constrained. Prices rise, but the overall market remains small.

Scenario 4: New indication redevelopment

A sponsor develops a modern formulation or pursues a new CNS indication. This could create new intellectual property, but it would be a separate development program with clinical, regulatory, and reimbursement risk.

How strong is the INVERSINE patent estate?

The patent estate is weak for the original product and hypertension indication.

Patent-strength factor	Assessment
Active composition patent	None identified
Active legacy formulation patent	None identified
Active hypertension method patent	None identified
Regulatory exclusivity	None established
Manufacturing barriers	Possible but not exclusive
Clinical differentiation	Limited
Supply-chain value	Potentially meaningful
Long-term pricing power	Low

The main defensible asset is not patent protection. It is operational capability: compliant manufacturing, stable API sourcing, validated analytical methods, regulatory maintenance, and distribution continuity.

What is the geographic coverage of INVERSINE?

INVERSINE is principally a U.S. legacy brand. Mecamylamine has had historical use outside the United States, but commercial availability, regulatory status, and branding vary by country. The small patient population and limited modern clinical demand reduce the probability of a broad international launch.

A geographic expansion strategy would face:

Country-specific registration requirements.
Limited guideline support.
Reimbursement uncertainty.
Small forecast volumes.
Local pharmacovigilance and supply obligations.
Competition from established antihypertensive generics.

The commercial case is stronger in jurisdictions where mecamylamine has an existing regulatory record or where specialist demand supports a small-volume product.

Key Takeaways

INVERSINE is the legacy brand for mecamylamine hydrochloride, an old oral ganglionic blocker for hypertension.
Its original patents and any practical regulatory exclusivity have expired.
No active, material patent estate is identified for the legacy tablet or hypertension use.
INVERSINE has no biosimilar exposure; its principal risks are generic competition, therapeutic substitution, and supply disruption.
Modern antihypertensive therapies sharply limit demand.
Public filings do not disclose standalone INVERSINE revenue or reliable product-level financial results.
Later mecamylamine CNS development created research value but did not establish a replacement commercial market.
The product’s strategic value depends more on supply reliability and niche clinical demand than on intellectual property.
A new formulation or indication could create a separate patent estate, but it would require new clinical and regulatory investment.

FAQs About INVERSINE

Is INVERSINE still a commercially important drug?

No. INVERSINE is a niche legacy product with limited demand and no visible blockbuster-scale revenue base.

Is mecamylamine available as a generic?

Mecamylamine is an old small-molecule active ingredient, but commercial generic availability depends on current FDA listings, manufacturer decisions, and supply conditions. Historical approval does not guarantee continuous market availability.

Can a company obtain new patents on mecamylamine?

Yes, a sponsor could pursue patents on a genuinely novel formulation, dosing regimen, combination, manufacturing process, or new therapeutic use. Such patents would not restore protection to the original INVERSINE tablet.

Was mecamylamine approved for smoking cessation?

Mecamylamine has been studied for smoking cessation and other CNS applications, but those investigations did not convert INVERSINE into an approved, high-revenue smoking-cessation product.

What is the investment case for INVERSINE?

The investment case is limited. Potential value could arise from supply scarcity, specialty distribution, or redevelopment into a protected indication. The legacy hypertension product alone has weak growth prospects, no meaningful patent moat, and no publicly established standalone revenue trajectory.

References

AstraZeneca. (2012). Annual report and Form 20-F 2011. AstraZeneca PLC.

Targacept, Inc. (2011). Annual report on Form 10-K for the fiscal year ended December 31, 2010. U.S. Securities and Exchange Commission.

U.S. Food and Drug Administration. (n.d.-a). Mecamylamine hydrochloride labeling and prescribing information. FDA.

U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. FDA.

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	80
Clinical Trials:	6
Patent Applications:	1,248
DailyMed Link:	INVERSINE at DailyMed

INVERSINE Drug Patent Profile

When do Inversine patents expire, and when can generic versions of Inversine launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Inversine

AI Deep Research

Questions you can ask:

Summary for INVERSINE

Recent Clinical Trials for INVERSINE

US Patents and Regulatory Information for INVERSINE

INVERSINE Market Dynamics, FDA Status, Patent Position, and Financial Trajectory